Browse the corpus

Acne vulgaris: Topical: Apply thin film 1-3 times/day Dosing: Pediatric Adolescents ≥12 years: Refer to adult dosing. Dosing: Geriatric Refer to adult dosing. Dosage Forms: U.S. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Lotion, topical: Vanoxide-HC®: Benzoyl peroxide 5% and hydrocortisone 0.5% (25 g) Lotion, topical [kit]: Vanoxide-HC®: Benzoyl peroxide 5% and hydrocortisone 0.5% (25 g) packaged with cleanser Generic Equivalent Available: U.S. No Administration Shake well prior to using; apply topically by gently massaging into skin Use Treatment of acne vulgaris and oily skin Adverse Reactions Significant See individual agents. Contraindications Hypersensitivity to benzoyl peroxide, hydrocortisone, or any component of the formulation; viral diseases of the skin (eg, varicella) Warnings/Precautions

Other warnings/precautions: • Appropriate use: For external use only; avoid contact with mucous membranes and eyes. Inform patients to use skin protection and minimize prolonged exposure to sun or tanning beds. Metabolism/Transport Effects Refer to individual components. Drug Interactions (For additional information: Launch Lexi-Interact™ Drug Interactions Program ) Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Risk X: Avoid combination Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Risk D: Consider therapy modification Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives. If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects. Risk D: Consider therapy modification Pregnancy Risk Factor C ( show table ) Pregnancy Implications Animal reproduction studies have not been conducted with this combination. See individual agents. Lactation Excretion in breast milk unknown/use caution Breast-Feeding Considerations See individual agents. Pricing: U.S. (Medi-Span®)

Lotion (Vanoxide-HC External) 5-0.5% (25 g): $61.97 International Brand Names Vanoxide-HC (CA) Pharmacodynamics/Kinetics See individual agents. Use of UpToDate is subject to the Subscription and License Agreement . Topic 8654 Version 36.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]